retatrutide type 2 diabetes phase 2 results 2024 ada Pharmacological therapies for diabetes: future approaches | Diabetologia Phase 2 trial results demonstrate

Rare, serious side effects like pancreatitis or gallbladder issues are not dose-related or directly caused by semaglutide in most cases

Researchers realized that if they could mimic your bodys natural GLP-1, they could help restore that internal balance

Members following the tirzepatide protocol reported outcomes consistent with the Surpass-1 clinical trial, which showed up to 31% reduction in fat mass over six months

Since, studies have attempted to elucidate the mechanisms governing this reduction and further identify the clinical utility of GLP-1RAs, but much must be inferred from preclinical studies in diabetic models